Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.91 USD
Change Today +0.04 / 0.82%
Volume 24.3K
FATE On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

fate therapeutics inc (FATE) Snapshot

Open
$4.94
Previous Close
$4.87
Day High
$5.06
Day Low
$4.75
52 Week High
03/31/14 - $11.08
52 Week Low
12/12/14 - $3.50
Market Cap
101.3M
Average Volume 10 Days
17.3K
EPS TTM
$-1.24
Shares Outstanding
20.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FATE THERAPEUTICS INC (FATE)

Related News

No related news articles were found.

fate therapeutics inc (FATE) Related Businessweek News

No Related Businessweek News Found

fate therapeutics inc (FATE) Details

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person’s lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person’s lifespan. The company’s lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

50 Employees
Last Reported Date: 03/12/15
Founded in 2007

fate therapeutics inc (FATE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $350.0K
Chief Operating Officer and Chief Financial O...
Total Annual Compensation: $256.0K
Compensation as of Fiscal Year 2013.

fate therapeutics inc (FATE) Key Developments

Fate Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Fate Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss and comprehensive loss of $6.233 million or $0.30 per basic and diluted common share compared to net loss and comprehensive loss of $5.74 million or $0.29 per basic and diluted common share a year ago. Loss from operations $5.943 million compared to $4.902 million a year ago. For the year, the company reported net loss and comprehensive loss of $25.9 million or $1.27 per basic and diluted common share compared to net loss and comprehensive loss of $20.9 million or $3.54 per basic and diluted common share a year ago. Loss from operations $24.904 million compared to $17.7 million a year ago.

Fate Therapeutics, Inc., Q4 2014 Earnings Call, Mar 12, 2015

Fate Therapeutics, Inc., Q4 2014 Earnings Call, Mar 12, 2015

Fate Therapeutics, Inc. Announces Executive Changes

Fate Therapeutics, Inc. announced that Wendy Levin, M.D., M.S. will join the company as vice president, clinical development and that Walter Grubb has joined the company as vice president, business development. Additionally, the company announced the promotion of John Ferraro to the newly-created position of vice president, clinical operations. Dr. Levin will play a critical role spearheading the company's clinical development of PROHEMA in patients with hematologic malignancies and rare genetic disorders. Dr. Levin, joins Fate Therapeutics from MEI Pharma, where she was vice president of clinical development and medical affairs. Mr. Grubb's responsibilities will include the assessment, valuation and licensing of business opportunities for the company. Mr. Grubb was previously executive director of business development and commercial operations at Ambit Biosciences, where he was responsible for multiple partnership transactions, provided commercial leadership for product candidates spanning a range of indications and stages of development, and was instrumental in the company's initial public offering and ultimate acquisition by Daiichi-Sankyo. Mr. Ferraro joined Fate Therapeutics in February 2013, and will be responsible for the company's clinical operations and data management functions. Prior to joining Fate, Mr. Ferraro was the senior director of clinical operations at GlobeImmune, Inc., where he established the clinical operations group and led the advancement of multiple targeted immunotherapies through the clinical development process in the United States and in Europe.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FATE:US $4.91 USD +0.04

FATE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FATE.
View Industry Companies
 

Industry Analysis

FATE

Industry Average

Valuation FATE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FATE THERAPEUTICS INC, please visit www.fatetherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.